Publications by authors named "S T Koz"
Article Synopsis
- The study aimed to assess how reverse micelles (RM) and hydrophobic ion pairs (HIP) can be used to incorporate semaglutide into self-emulsifying oral drug delivery systems.
- Researchers created RM using a cationic surfactant (ELA) and anionic surfactant (DOC) and explored various lipophilic phases to determine solubility and dissolution rates of semaglutide.
- The findings demonstrated that RM enhanced the lipophilicity and payload of semaglutide in SEDDS, with promising cytocompatibility and doubled permeability when tested on Caco-2 cells compared to HIP formulations.
Purpose: Alterations in skin structure and function are very common in uremic patients, but still there is no unifying hypothesis for uremic skin disorders. Fibroblast growth factor-23 (FGF-23) deficiency has been linked to skin disorders in non-uremic animals. We aimed to study alterations in FGF-23 and fibroblast growth factor-23 receptor 1 (FGFR1) expression in uremic rat skins.
View Article and Find Full Text PDFBackground: Limited data suggest that health literacy (HL) is associated with kidney functions and clinical outcomes in patients with non-dialysis chronic kidney disease (CKD). We aimed to identify factors associated with the level of HL in a CKD population that has not been studied previously.
Methods: Patients with stage I-V (non-dialysis) CKD according to the Kidney Disease Outcomes Quality Initiative classification were enrolled in the study from two tertiary healthcare centers.
Background: Plasma level of N-terminal pro-brain natriuretic peptide (P-NTproBNP) is a useful marker in prediction of mortality in peritoneal dialysis (PD) patients. However, the predictive value of spent dialysate counterpart (D-NTproBNP) of plasma NTproBNP on mortality and dropout is not known.
Materials And Methods: Simultaneous P-NTproBNP and D-NTproBNP assays were performed after an overnight dwell in 44 scheduled ambulatory PD patients.
Background: Brain natriuretic peptide and its derivative peptide NTproBNP are utilized to exclude cardiac diseases, and predicting risk of mortality in dialysis patients. Our aim was to evaluate both elimination of NTproBNP through dialysate and a possible relationship between plasma and/or dialysate NTproBNP level and membrane transport status of peritoneal dialysis patients.
Methods: 57 plasma (P) and dialysate (D) samples of 44 peritoneal dialysis (PD) patients were analyzed for NTproBNP.